论文部分内容阅读
目的探讨吉非替尼治疗非小细胞肺癌(NSCLC)脑转移的疗效及其对预后的影响。方法44例NSCLC脑转移患者中,接受过全脑放疗者30例,接受过化疗者42例,均在入组前1个月结束治疗。入组者口服吉非替尼250 mg,每日1次,服药至疾病进展或死亡。服药后定期复查。结果吉非替尼治疗的有效率为31.8%,稳定率为47.7%,临床获益率为79.5%。中位无进展生存时间为9个月,中位总生存时间为13个月。吉非替尼对颅内转移灶的控制率达81.9%。既往接受全脑放疗患者与未接受全脑放疗者相比,其转移灶控制率差异无统计学意义(P=0.566)。结论吉非替尼治疗NSCLC脑转移的疗效显著,不良反应轻微,能明显改善患者预后,是晚期NSCLC患者的治疗方法之一。
Objective To investigate the curative effect of gefitinib on brain metastasis of non-small cell lung cancer (NSCLC) and its effect on prognosis. Methods Totally 44 patients with brain metastases of NSCLC received 30 patients with whole brain radiation and 42 patients who received chemotherapy. All patients were treated one month prior to enrollment. Participants oral gefitinib 250 mg once daily, medication to disease progression or death. After taking regular review of medication. Results Gefitinib treatment of the effective rate was 31.8%, the stability rate was 47.7%, the clinical benefit rate was 79.5%. The median progression-free survival time was 9 months and the median overall survival time was 13 months. Gefitinib on the control of intracranial metastases rate of 81.9%. There was no significant difference in the control rate of metastases between patients who received whole brain radiation and those who did not receive whole brain radiation (P = 0.566). Conclusion Gefitinib treatment of NSCLC brain metastases significant effect, mild adverse reactions, can significantly improve the prognosis of patients with advanced NSCLC is one of the treatment methods.